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Abstract 
Importance: Barrett esophagus containing low-grade dysplasia is associated with an increased risk of 
developing esophageal adenocarcinoma, a cancer with a rapidly increasing incidence in the Western 
world.  
Objective: We investigated whether endoscopic radiofrequency ablation could decrease the rate of 
neoplastic progression.  
Design, Setting and Participants: Multicenter randomized clinical trial that enrolled 136 patients with 
a confirmed diagnosis of Barrett esophagus containing low-grade dysplasia, at 9 European sites and 
conducted between June 2007 and June 2011. Patient follow-up ended May 2013. 
Interventions: Eligible patients were randomly assigned 1:1 to either endoscopic treatment with 
radiofrequency ablation (ablation) or endoscopic surveillance (control). Ablation was performed with 
the balloon device for circumferential ablation of the esophagus or the focal device for targeted 
ablation, with a maximum of 5 sessions allowed. 
Main outcomes: The primary outcome was neoplastic progression to high-grade dysplasia or 
adenocarcinoma during a 3–year follow-up since randomization. Secondary outcomes were complete 
eradication of dysplasia and intestinal metaplasia, and adverse events.  
Results: 68 patients were randomized to ablation and 68 to control. The planned enrollment was 
126. Ablation reduced the risk of progression to high-grade dysplasia or adenocarcinoma by 25.0% 
(1.5% vs. 26.5%, 95% CI: 14.1-35.9; p<0.001) and the risk of progression to adenocarcinoma by 7.3 
(1.5% vs. 8.8%, 95% CI 0.0-14.7; p=0.026). Complete eradication of dysplasia and intestinal 
metaplasia occurred in 92.6% and 88.2% of patients in the ablation group, respectively, compared to 
27.9% and 0.0% of patients in the control group, respectively (p<0.001). Treatment-related adverse 
events occurred in 19.1% of ablation patients (p<0.001). The most common adverse event was 
stricture, occurring in eight ablation patients (11.8%), all resolved by endoscopic dilation (median 1 
session). The Data and Safety Monitoring Board recommended early termination of the trial due to 
superiority of ablation for the primary outcome and the potential for patient safety issues if the trial 
continued. 
Conclusions and relevance: In a randomized trial of patients with Barrett esophagus with a 
confirmed diagnosis of low-grade dysplasia, radiofrequency ablation resulted in a reduced risk of 
neoplastic progression over 3 years of follow-up. 
Trial Registration: trialregister.nl  Identifier: NTR 1198 
 
Funding: Dutch Digestive Diseases Foundation, Covidien GI Solutions (formerly BÂRRX Medical). 
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Introduction 
In the last three decades, the incidence of esophageal adenocarcinoma has increased six-fold, 
making it the most rapidly rising cancer in the Western world.1 Esophageal adenocarcinoma 
originates from Barrett esophagus, a metaplastic change in the epithelium of the esophagus caused 
by gastro-esophageal reflux disease. The histological landmark of Barrett esophagus is the presence 
of intestinal metaplasia. General population data are scarce, but the prevalence of Barrett esophagus 
is estimated to be 1.6% in Europe, compared to estimates between 1.7%-5.6% in the US. Incidence 
rates vary between 23.1-32.7 per 100,000 person-years.2–6 Malignant degeneration is thought to 
occur in a step-wise fashion from non-dysplastic intestinal metaplasia, to low- then high-grade 
dysplasia, and eventually adenocarcinoma.7,8 Patients with Barrett esophagus undergo endoscopic 
surveillance or treatment, depending on the presence and grade of dysplasia.8 
Radiofrequency ablation is an established endoscopic technique for eradication of Barrett esophagus 
which has been investigated in a variety of study designs (including two randomized trials), and 
settings (US and EU, tertiary academic centers, community referral centers).9–13 Radiofrequency 
ablation is associated with an acceptable safety profile, high rates of complete eradication of 
dysplasia and intestinal metaplasia, durability of effect, and a significant relative risk reduction for 
neoplastic progression.9–13 As a result, radiofrequency ablation is considered standard of care for 
patients with high-grade dysplasia, as well as for residual Barrett tissue after endoscopic resection of 
early cancer.14 To date, no trial has evaluated the effect of radiofrequency ablation on the risk of 
neoplastic progression in patients with Barrett esophagus containing low-grade dysplasia. Most 
guidelines advise endoscopic surveillance (every 6 to 12 months) to monitor for neoplastic 
progression in this patient population.8,15–17 There are, however, uncertainties related to the 
diagnosis and natural course of low-grade dysplasia: whereas some patients may progress to high-
grade dysplasia or adenocarcinoma, others may remain stable or may not even have their diagnosis 
reproduced over time.18 A recent study, however, indicated that progression to high-grade dysplasia 
or adenocarcinoma occurs at a rate of 13.4% per patient year in this patient population, provided 
that the baseline diagnosis has been confirmed by expert pathologists.19 Given this significant risk of 
progression,, endoscopic treatment in this patient population may be justified . This is a clinically 
important question since 25-40% of Barrett esophagus patients are diagnosed with low-grade 
dysplasia at some point during follow-up.18 
We conducted a multicenter randomized, trial, the SURF study (Surveillance vs. Radiofrequency), 
comparing radiofrequency ablation with endoscopic surveillance in patients with Barrett esophagus 
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and a confirmed diagnosis of low-grade dysplasia. In both groups, we assessed the rate of 
progression to high-grade dysplasia and adenocarcinoma.  
 
Methods 
Study design and patients 
The trial was conducted at 9 Barrett treatment centers in Europe. The Institutional Review Board at 
each center approved the study protocol (NTR1198, www.trialregister.nl). Written informed consent 
was obtained from all study patients. Prior to the start of the trial all of the investigators received 
hands-on training in ablation at the coordinating study site by the principal investigator of the trial. 
An independent Data and Safety Monitoring Board (DSMB) monitored the trial with standardized 
adverse event reporting procedures and. interim analyses at t=0.5 and t=0.75, with a nominal cut-off 
value of p<0.0031 based on the O’Brien-Fleming method. Independent study monitors attended all 
study procedures and verified all recorded data.  
Eligible patients had undergone upper endoscopy and biopsy within the previous 18 months 
demonstrating Barrett esophagus containing low-grade dysplasia. The local pathologist’s diagnosis 
was confirmed by the expert central pathology panel (FtK, MV, KS, JO, SM). Exclusion criteria were 
prior endoscopic treatment for Barrett esophagus, history of high-grade dysplasia or 
adenocarcinoma, active secondary malignancy, estimated life-expectancy <2 years (according to the 
enrolling physician), and age <18 years or >85 years. 
All patients required a baseline qualifying endoscopy <6 months prior to randomization to exclude 
visible abnormalities, high-grade dysplasia, or adenocarcinoma, which was performed using high-
resolution endoscopy with biopsies obtained according to the Seattle protocol (4-quadrant 
biopsies/2cm) and from any visible abnormalities. Visible abnormalities were defined as any mucosal 
irregularity or discoloration within the a Barrett esophagus.  
Randomization 
Patients were randomly assigned in a 1:1 ratio to receive either endoscopic radiofrequency ablation 
(ablation) or endoscopic surveillance (control). The randomization sequence was concealed from trial 
staff, who screened eligible patients. After informed consent had been obtained, assignment was 
made by the central study monitor using sequentially numbered, sealed opaque envelopes, and 
conveyed to the site by telephone. 
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Ablation 
Within one month after randomization, patients assigned to ablation were treated with a 
circumferential device (HALO360 system) or a focal device (HALO90) (Covidien GI Solutions (formerly 
BÂRRX Medical),  Sunnyvale, CA, USA) according to extent of disease and investigator preference 
(Figure 1A-1E).20,21 Subsequent ablation sessions occurred every 3 months, until complete 
endoscopic and histological eradication of Barrett esophagus (Figure 1F), or a maximum of 2 
circumferential and a maximum of 3 focal sessions. At each ablation session, the squamocolumnar 
junction was ablated circumferentially, irrespective of its endoscopic appearance. If residual 
columnar epithelium persisted after the maximum allowable number of ablations, a single session of 
endoscopic resection or argon plasma coagulation (for ≤4 Barrett esophagus islands, ≤5mm) was 
allowed per protocol.10 All procedures were performed on an outpatient basis using midazolam plus 
fentanyl/pethidine, or propofol.   
The first follow-up endoscopy was scheduled 3 months after the last therapeutic endoscopy. 
Subsequent follow-up endoscopies were performed annually thereafter until 3 years after 
randomization (2 years after completion of ablation). At each follow-up endoscopy, 4-quadrant 
biopsies were obtained every 2-cm of the original extent of the Barrett esophagus, starting one cm 
proximal to the top of the gastric folds. In addition 4 biopsies were obtained from the gastric cardia, 
<5-mm distal to the neo-squamocolumnar junction.  
During the trial, ablation patients received double-dose proton pump inhibition as maintenance 
therapy. A H2-receptor antagonist and sucralfate suspension was added for 2 weeks after each 
therapeutic endoscopy.  
Control 
Patients assigned to control underwent high-resolution endoscopy at 6 and 12 months after the 
baseline qualifying endoscopy, and annually thereafter until 3 years after randomization. At each 
follow-up endoscopy, 4-quadrant biopsies were obtained from every 2-cm of Barrett epithelium.  If 
histology showed either low-grade dysplasia or no dysplasia, patients were scheduled for follow-up 
according to the study protocol. 
Histologic analysis 
Follow-up esophageal biopsy specimens were processed and locally evaluated at each of the nine 
participating centers. Each specimen was assessed for the presence of intestinal metaplasia (as the 
histological feature of residual Barrett esophagus) and grade of dysplasia according to the Vienna 
classification.22 In cases of post-randomization biopsies locally read as high-grade dysplasia or 
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adenocarcinoma, confirmation of this primary outcome required agreement by 2 pathologists from 
the central expert pathologist panel. The central pathologist was not informed on the exposure 
status of the patient. In case of discordance, a third central expert pathologist interpretation was 
employed as a tiebreaker, or the panel reviewed the slides mutually and reached a consensus 
diagnosis.  
Outcome measures 
The primary outcome was occurrence of high-grade dysplasia or adenocarcinoma (i.e., neoplastic 
progression) at any time during the 3 years following randomization. Secondary outcomes were: 
complete histological eradication of dysplasia (i.e. absence of dysplasia of any grade in all biopsies 
obtained at the first follow-up endoscopy) and intestinal metaplasia (i.e. absence of intestinal 
metaplasia in all biopsies obtained at the first follow-up endoscopy), and adverse events. Patients 
who met the primary outcome were considered failures for the secondary outcome of complete 
eradication. Patients who met the primary outcome were treated at investigator’s discretion, per 
standards for high-grade dysplasia and adenocarcinoma at that institution. 
Statistical analysis 
We estimated that ablation would produce a 90% relative risk reduction for progression to high-
grade dysplasia or adenocarcinoma, using prior studies of the outcomes of ablation.20,21,23 We 
assumed that 14% of control and 1% of ablation patients would develop high-grade dysplasia or 
adenocarcinoma during the 3-year follow-up. We projected that with a sample size of 120 patients, 
the study would have at least 80% statistical power to detect the hypothesized differences in the 
primary outcome variable between the groups. Based on an anticipated 5% dropout rate, we sought 
to enroll 126 patients. 
The modified intention-to-treat population included all randomized patients meeting all study 
criteria. The time to progression was calculated from the date of randomization until the endoscopy 
date on which high-grade dysplasia or adenocarcinoma was first detected. The proportional event 
rates during follow-up were compared by Kaplan-Meier analysis and log-rank test. Risk differences 
were calculated as the difference in the proportional event rates during follow-up. Number needed 
to treat was calculated as 1 divided by the risk difference. For the primary outcome (in view of the 
use of the O’Brien-Fleming rule) a two-tailed p-value <0.0440 was considered to indicate statistical 
significance.   
Categorical variables were compared using the Fisher’s exact test. Continuous variables are 
presented as means (±SD) and were compared using Student’s t-test in case of a normal distribution, 
or presented as median (IQR) and compared using the Mann-Whitney U test in case of a skewed 
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distribution. We conducted subgroup analyses for risk factors of progression and absence of low-
grade dysplasia during follow-up by means of logistic regression. In the multivariable regression 
model, baseline variables were identified with a forward stepwise selection strategy using the 
likelihood ratio statistic, with p<0.10 the criterion level for selection. For data analysis the SPSS 
statistical software package (SPSS 20.0.1, IBM Corp., Armonk, NY, USA) was used.   
Results  
Patients were enrolled between June 2007 and June 2011 in 9 centers from 5 European countries. Of 
511 patients screened, 140 were included and randomized (Figure 2). Four patients (2 ablation, 2 
control) were excluded from analysis because of inadvertent randomization, after re-assessment of 
pre-randomization histology and/or endoscopy demonstrated study exclusion criteria (Figure 2). The 
remaining 136 patients (68 ablation, 68 control) were included in the modified-intention-to-treat 
population. The two groups were similar in their baseline characteristics (Table 1).  
Upon review of the second planned interim analysis in April 2013, the DSMB recommended early 
termination of the trial due to superiority of ablation for the primary outcome and the potential for 
patient safety issues if the trial continued. The stopping rule was followed by the DSMB after the pre-
planned O’Brien-Fleming method demonstrated superiority. The steering committee subsequently 
closed the trial on May 8th, 2013. At that time, all patients were followed for at least 24 months, with 
a median follow-up of 36 months and an interquartile range varying from 30 to 36 months. 
Patients treated with ablation were less likely, compared to control, to progress to high-grade 
dysplasia or adenocarcinoma (1.5% vs. 26.5%, p<0.001) and less likely to progress to adenocarcinoma 
(1.5% vs. 8.8%, p=0.026) (Table 2). Ablation reduced the risk of progression to high-grade dysplasia 
or adenocarcinoma by 25.0% (95% CI 14.1-35.9), with a number needed to treat of 4.0 (95% CI 2.8-
7.1) (Figure 3). Ablation reduced the risk of progression to adenocarcinoma by 7.4% (95% CI 0.0-
14.7), with a number needed to treat of 13.6 (95% CI 6.8-∞).  
The ablation group had one patient that progressed (adenocarcinoma). This patient was treated with 
endoscopic resection, and achieved complete eradication of dysplasia. The control group had 18 
patients that progressed (12 high-grade dysplasia, 6 adenocarcinoma).  One control patient with 
adenocarcinoma underwent esophagectomy for poorly differentiated submucosal carcinoma. No 
residual cancer or positive lymph nodes were detected and the patient remains free of disease after 
37 months of follow-up. Of the remaining 17 control patient progressors, fifteen (10 high-grade 
dysplasia, 5 mucosal adenocarcinoma) underwent endoscopic resection (n=9, median 4 resections, 
range 1-14) and/or radiofrequency ablation (n=15). Eleven of fifteen achieved complete eradication 
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of dysplasia and intestinal metaplasia, while four are still under treatment. The remaining two 
progressors (2 high-grade dysplasia) opted for endoscopic surveillance.   
Complete eradication of dysplasia and intestinal metaplasia occurred in 92.6% (63/68) and 88.2% 
(60/68) of ablation patients, respectively. During the follow-up phase of the trial, complete 
eradication of dysplasia was maintained in 62 of 63 (98.4%) ablation patients. In the control group, 
low-grade dysplasia was not detected during the follow-up period in 19 of 68 patients, resulting in 
complete eradication of dysplasia of 27.9% (risk difference 71%, 95%CI 59-82; p<0.001). Complete 
eradication of intestinal metaplasia was maintained in 54 of 60 ablation patients (90.0%),compared 
with 0 of 68 control patients (0%) (risk difference, 90%, 95% CI 82-98; p<0.001). All recurrences in the 
ablation group were small islands or tongues <10-mm (Table 2). 
Ablation patients underwent 211 ablation sessions (median 3 per patient) and 208 endoscopic biopsy 
sessions (median 3 per patient, median 37 biopsies per patient). Escape endoscopic resection and 
argon plasma coagulation was used in 5 (7.4%) and 12 (17.6%) ablation patients, respectively. Control 
patients underwent 227 endoscopy and biopsy sessions (median 3 per patient; median 32 biopsies 
per patient).   
There were 3 serious adverse events in 2 ablation patients. One patient was hospitalized for 
abdominal pain four days after ablation, treated to resolution with analgesics. A second patient 
experienced bleeding 7 days after endoscopic resection for a visible lesion (low-grade dysplasia), 
prior to the first ablation. Later, this same patient was dilated for stricture and developed fever and 
chills. No perforation was noted and the patient was hospitalized and treated with antibiotics. There 
were 12 adverse events in 12 ablation patients. During ablation, a small mucosal laceration was 
noted in three patients (no intervention required, procedure completed). One patient reported 
retrosternal pain three weeks after focal ablation. Endoscopy was normal and the pain resolved with 
analgesics. Eight patients (11.8%) developed esophageal stricture requiring dilation (median 1 
dilation, IQR 1-2). There were no adverse events in control patients (risk difference 19%, 95% CI 
(9.7%-28.4%; p<0.001). 
Multivariable analysis (Model-fit significance 0.001, Nagelkerke R2 0.35) demonstrated that the 
number of years since the diagnosis of Barrett esophagus (OR 0.84; 95% CI 0.72-0.98), the number of 
endoscopies with dysplasia prior to inclusion (OR 1.44; 95% CI 1.03-2.03), and circumferential Barrett 
esophagus length in centimeters (OR 1.35; 95% CI 1.04-1.76) were independent predictors of 
progression in the control group (Table 3). Multivariable analysis could not identify significant 
predictors for absence of low-grade dysplasia during surveillance in the control group (data not 
shown).   
SURF Trial: Surveillance vs. Radiofrequency Ablation for LGD in BE 
JAMAR1-6 February 
 
Page 9 of 22 
Discussion 
In this randomized trial of ablation vs. surveillance in patients with Barrett esophagus with a 
confirmed diagnosis of low-grade dysplasia, ablation reduced the risk of progression to high-grade 
dysplasia or adenocarcinoma from 26.5% to 1.5% (p<0.001), an absolute risk reduction of 25.0% (95% 
CI 14.1-35.9) corresponding to a number needed to treat of 4.0. In addition, ablation reduced the risk 
of progression to adenocarcinoma, from 8.8% to 1.5% (p=0.026), an absolute risk reduction of 7.4% 
(95% CI 0.0-14.7), corresponding to a number needed to treat of 13.6.  Of patients who underwent 
ablation, 92.6% achieved complete eradication of dysplasia, versus 27.9% in controls. Complete 
eradication of intestinal metaplasia was achieved in 88.2% of patients, versus 0.0% in controls. 
Follow-up after ablation showed that eradication of dysplasia and intestinal metaplasia persisted in 
the majority of patients. These results comport with those of previous prospective studies of ablation 
for HGD and adenocarcinoma in Barrett esophagus.9,12,24 
This trial was terminated early, upon recommendation of the Data and Safety Monitoring Board, due 
to superiority of ablation for the primary endpoint and concerns about patient safety should the trial 
continue.  Early termination did not affect patient enrollment and only led to shortening of the 
follow-up from the intended 3-years to 2-years in 40% of patients. In the remaining patients 3-years 
follow-up was achieved. Given the minimal loss of longitudinal data, the profound differences 
between the groups in disease progression made it unjustified to continue the trial for an additional 
year.  
Our data suggest that endoscopic ablative therapy is a superior management strategy to endoscopic 
surveillance in subjects with Barrett esophagus and confirmed low-grade dysplasia.  Given the high 
rate of malignant degeneration in our control group, and the relatively low number needed to treat 
to avert a single progression, as well as the acceptable safety profile, a paradigm shift to earlier 
endoscopic intervention in this patient population deserves consideration. 
Of note, no control patient demonstrated unresectable cancer or cancer-related death.  While the 
lack of cancer-associated mortality might suggest that endoscopic surveillance remains an 
appropriate management strategy for low-grade dysplasia, we would advise caution with this 
interpretation.  Our patients were maintained in a trial setting, and despite rigorous monitoring at 
expert centers, one of our control patients did require esophagectomy for development of advanced 
stage disease. Outside of a rigorous study protocol, neoplastic progression in subjects undergoing 
endoscopic surveillance might be detected at a later stage.  If so, the neoplasia might not be 
amenable to endoscopic therapy, and henceforth be associated with higher rates of surgery, 
unresectable disease, and cancer-related death. 
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A wide range of neoplastic progression rates have been reported for Barrett esophagus with low-
grade-dysplasia. The observed rate of progression in our control group (26.5% overall; 11·8% per 
patient year of follow-up) comports with rates from studies requiring expert GI pathologist 
confirmation. 7,13,17  The observed progression rate in our control group, however, contrasts with 
lower rates from other studies  (1.4%- 1.83% per patient year) with no expert confirmation of 
baseline diagnosis or poor interobserver agreement.15–17  After expert pathology review, 50-85% of 
patients initially diagnosed with low-grade dysplasia may be down-staged to non-dysplastic Barrett’s 
with an associated lower risk of neoplastic progression.19,25 Expert pathology review by a panel of 
experienced pathologists with an acceptable inter-observer agreement (kappa 0.50 for our panel19) is 
therefore important to accurately ascertain patient risk for progression and determining which 
patients would benefit from treatment vs. surveillance. 
Of note, 28% of controls had no dysplasia detected during follow-up. This proportion is similar to the 
randomized trial by Shaheen et al. where 26% of low-grade controls did not show dysplasia at 12 
months follow-up.12  Ideally, ablation should be avoided in these patients, given their lower risk of 
progression and the associated risks and costs of treatment, however we don’t know in advance 
which patients will fail to demonstrate LGD over time. In our trial, histological confirmation of low-
grade dysplasia by an expert pathologist was the most important selection criterion. Risk of 
progression may, however, depend on additional factors. Patients harboring multifocal dysplasia in 
their Barrett esophagus segment likely carry an increased risk for progression compared to patients 
with only focal dysplasia (spatial distribution).26 Second, low-grade dysplasia on multiple endoscopies 
likely increases the risk of progression compared to a single endoscopy diagnosis (temporal 
distribution).27  In our study, a single confirmed diagnosis of low-grade dysplasia sufficed for 
enrollment, yet the number of endoscopies with dysplasia prior to inclusion was an independent 
predictor for progression in the multivariable analysis. Insisting that a confirmed diagnosis of low-
grade dysplasia is reproduced over time may therefore improve the selection of patients for ablation. 
Adequate endoscopic inspection is, however, required to avoid that patients progress to advanced 
neoplasia during this lag time: 14% of patients were excluded because high-grade dysplasia or 
adenocarcinoma was diagnosed at the baseline qualifying endoscopy, and 10 of our 19 progressors 
were diagnosed within 12 months follow-up.   
Ablation treatment was generally safe with esophageal stricture being the most common 
complication (11.8%), requiring median 1 dilation. This is higher than the 5%  pooled estimate of a 
recent meta-analysis, however this analysis was limited by heterogeneity of the included studies of 
which half were retrospective studies.28  Although we found a higher stricture rate in our trial, our 
strictures were generally mild in nature, given the low average number of required dilations. In 
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comparison, the average number of required dilations for stricture after ablation in the AIM 
Dysplasia trial was 2.6.12      
Strengths of our study include a small proportion of patients lost-to-follow-up, centralized expert 
pathology review, rigorous quality control, expert center participation, hands-on training for 
investigators, and procedure supervision by study coordinators.  Limitations of our study include 
exclusive participation of expert referral centers, which may render these results less generalizable to 
general practice. In our opinion endoscopic work-up, treatment and follow-up of Barrett esophagus 
with dysplasia should be restricted to centers with extensive expertise in this field. Second, our 
primary endpoint was progression to a combined endpoint of high-grade dysplasia or 
adenocarcinoma and our trial was underpowered for a “cancer-related death” endpoint. However, 
progression to high-grade dysplasia/adenocarcinoma is the most clinically relevant and appropriate 
endpoint, as both are presently considered indications for endoscopic treatment. Third, a confirmed 
diagnosis of low-grade dysplasia at one endoscopy session sufficed for inclusion in the study.  Fourth, 
we allowed endoscopic rescue therapy in a small number of patients for diminutive residual Barrett 
tissue.  
 Conclusions 
In this multicenter, randomized trial of radiofrequency ablation versus surveillance in patients with a 
Barrett esophagus and a confirmed histological diagnosis of low-grade dysplasia, ablation 
substantially reduced the rate of neoplastic progression to high-grade dysplasia and adenocarcinoma 
over 3 years of follow-up. Patients with a confirmed diagnosis of low-grade dysplasia should 
therefore be considered for ablation therapy. 
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Figure 1. Radiofrequency ablation treatment in a patient with Barrett esophagus and low-grade dysplasia 
An endoscopic image shows the distal esophagus at the baseline endoscopy, looking toward the gastro-esophageal junction (A). A deflated circumferential 
radiofrequency ablation balloon is positioned in the segment of Barrett esophagus. The immediate treatment effect of the circumferential ablation can be 
seen (B). The focal radiofrequency ablation device is used for targeted ablation of a small area of residual Barrett epithelium (C). An endoscopic photograph 
shows the distal esophagus after complete eradication of all Barrett epithelium (D). Shown images do not correspond to the same patient.  
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Figure 2. Enrollment and outcomes. 
BQE denotes baseline qualifying endoscopy; FU denotes follow-up; HGD denotes high-grade 
dysplasia; LGD denotes low-grade dysplasia; NDBE denotes non-dysplastic Barrett esophagus.  
 
 
Figure 3. Occurrence of progression to high-grade dysplasia or adenocarcinoma.  
 
 
Shown is the rate of progression to high-grade dysplasia or cancer, in the two study groups. Using 
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Table 1. Demographic and disease-specific characteristics of enrolled patients.* 
* Plus-minus values are means±SD and were compared using independent T-test. Categorical data 
were compared using Fisher’s Exact test. There were no significant differences between the two 
study groups. 
† Race or ethnic group, history of reflux disease and use of proton-pump inhibitors were self 
reported. 
‡ The body mass-index is the weight in kilograms divided by the square of the height in meters.  
¶ Data are shown as median (IQR) and were compared using Mann-Whitney U test. There were no 
significant differences between the two study groups.  






Age – yr 63±10 63±9 
Male sex – no. (%) 55 (81) 61 (90) 
Whiterace or ethnic group – no. (%) † 66 (97) 66 (97) 
Body Mass Index ‡ 26.8±3.7 27.9±4.8 
Circumferential Barrett esophagus – cm ¶/¥ 
 
2 (0-6) 2 (1-4) 
Maximum Barrett esophagus – cm ¶/¥ 
 
4 (2-8) 4 (3-6) 
Time since diagnosis of Barrett esophagus – yr ¶ 5 (2-10) 7 (3-11) 
Time since diagnosis of dysplasia – yr ¶ 1 (0-5) 2 (0-5) 
Barrett surveillance endoscopies prior to baseline – 
no. ¶ 
5 (3-8) 5 (3-7) 
Barrett surveillance endoscopies with dysplasia 
prior to baseline – no. ¶ 
2 (1-4) 2 (1-3) 
Reported history of gastro-esophageal reflux 
disease – no. (%) † 
62 (91) 65 (96) 
Reported use of proton-pump inhibitor – no. (%) † 68 (100) 67 (99) 
Use of proton-pump inhibitors – yr ¶ 8 (5-14) 9 (4-14) 
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Table 2. Primary and secondary efficacy outcomes. 
 
* Two-sided p-values were derived using log-rank testing on Kaplan-Meier estimates.  
‡ Including one patient who died of metastasised lung carcinoma after the second ablation 
treatment and one patient who had esophageal adenocarcinoma diagnosed after the fourth ablation 
session as failures for complete eradication of dysplasia and intestinal metaplasia.  
¶ If, at any follow-up endoscopy biopsies showed intestinal metaplasia or low-grade dysplasia, this 











 Patients with Event Patients with Event    
 no. (%) no. (%) % %  
Progression to high-grade 
dysplasia or cancer 
1 (1.5) 18 (26.5) 25.0 14.1-35.9 <0.001 
Progression to cancer 1 (1.5) 6 (8.8) 7.3 0.0-14.7 0.026 
      
Complete eradication of 
dysplasia at the end of 
endoscopic treatment 
63/68 (92.6)‡ -- -- -- n.a. 
Complete eradication of 
IM at the end of 
endoscopic treatment 
60/68 (88.2)‡ -- -- -- n.a. 
   -- --  
Complete eradication of 
dysplasia during follow-up¶ 
62/63 (98·4)‡ 19/68 (27·9) 70.5 59.4-81.6 <0.001 
Complete eradication of 
IM during follow-up¶ 
54/60 (90·0)‡ 0/68 (0·0) 90.0 82.4-97.6 <0.001 
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Variable Odds Ratio (95% CI) p value Odds Ratio (95% CI) p value 
Age - yr 0.94 (0.88-1.00) 0.06 0.92 (0.85-1.00) 0.05 
Body Mass Index 1.06 (0.94-1.18) 0.36 
  
Circumferential Barrett esophagus - cm 1.12 (0.93-1.34) 0.25 1.35 (1.04-1.76) 0.03 
Maximum Barrett esophagus - cm 1.05 (0.86-1.28) 0.63 
  
Time since diagnosis of Barrett esophagus - yr 0.88 (0.77-0.99) 0.04 0.84 (0.72-0.98) 0.02 
Time since diagnosis of dysplasia - yr 1.00 (0.97-1.03) 0.86 
  
Barrett surveillance endoscopies prior to 
baseline - no 0.97 (0.78-1.20) 0.77 
  
Barrett surveillance endoscopies with 
dysplasia prior to baseline - no 1.24 (0.94-1.63) 0.12 1.44 (1.03-2.03) 0.03 
Use of proton-pump inhibitors - yr 0.96 (0.91-1.05) 0.49 
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